Latest research on Mometasone Furoate

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. he antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

Mometasone Furoate side effects

Thus it is better to use Nasal steroid as it minimizes systemic side effects of corticosteroids especially with Mometasone Furoate, which is known by its low bioavailability. [source, 2015]
Three compounds, cilnidipine (C), Mometasone Furoate (MF), and Nicardipine Hydrochloride (NH) significantly decreased NF-κB activity in FXR transfected cells. [source, 2015]
W. et al. The glucocorticoid Mometasone Furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression. [source, 2015]
A pilot analysis was performed utilizing the Bcc strains that exhibited increased C. elegans susceptibility in numerous efflux knock-outs on SKA (B. ambifaria, B. arboris, B. cepacia, B. dolosa, B. pyrrocinia) and the well-characterized mammalian MRP-efflux inhibitors Mometasone Furoate, lasalocid A and verapamil [51]. [source, 2015]
In another study, Fluticasone did not cause Cortisol suppression or major skin atophy, and was similar to Mometasone Furoate in efficacy [49]. [source, 2014]
After 15 days of treatment in the Mometasone Furoate in MLE group, the TEWL improvement ratio, which was 48.30±68.04% at baseline, was statistically significant; and in the Methylprednisolone acetonate group, the TEWL improvement ratio increased 32.74±50.07% from baseline after 15 days. [source, 2013]
Although the TEWL improvement ratio increased in both groups, the TEWL improvement ratio in the Mometasone Furoate in MLE group was superior to that in the Methylprednisolone acetonate group (p≤0.0001). [source, 2013]
After 15 days of treatment, the VAS improvement ratio score increased 83.28±23.47% from baseline in the Mometasone Furoate in MLE group and 75.41±27.24% in the Methylprednisolone group. [source, 2013]
Mometasone Furoate (MF) is a potent ICS with relatively low potential to cause significant systemic side effects typically associated with oral corticosteroids, such as hypothalamic-pituitary-adrenal axis suppression. [source, 2013]
The total MCA1 increased from 0.42 to 0.47 cm2 after 1 month of treatment and further improved to 0.50 cm2 after 2 months for patients treated with Mometasone Furoate NS. [source, 2013]